Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Non-invasive Diagnosis of Invasive Pulmonary Aspergillosis by Use of Biomarkers in Exhaled Breath Condensate

A legfontosabb adatok

Ki végzi
Inger Lise Gade
Hol
Dánia1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Résztvevők
101 fő vett részt
Kezdés
2020. ápr. 17.
Befejezés
2023. dec. 31.
A vizsgálat típusa
Megfigyeléses, 6 csoport
A vizsgált kezelések
  • Aspergillus specific proteins in exhaled breath condensate (EBC)
  • Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)
A regiszteradat frissítve
2024. február 13.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 6 feltétel megnézéseKevesebb

Ki vehet részt

  • Suspected/confirmed PA patients:; Hospitalized or ambulatory patients with a suspected PA at Aalborg University Hospital; Are conscious and able to understand the given study information; Possess legal capacity; Age above 18 years; Informed, signed consent is obtained; Clinically stable, which is defined as patients with stable blood pressure and not in need for other treatments; No need for organ support, which comprises need for vasopressors or inotropes, mechanical ventilation, extra corporal circulation or renal replacement therapy
  • Controls; Patients as the PA patients, but where the diagnosis of PA is rejected will be included as controls
  • Suspected/confirmed pneumocystis pneumonia patients:; Hospitalized or ambulatory patients with a suspected pneumocystis pneumonia at Aalborg University Hospital - chest x-ray must support the tentative diagnosis of pneumocystis pneumonia; Are conscious and able to understand the given study information; Possess legal capacity; Age above 18 years; Informed, signed consent is obtained; Clinically stable, which is defined as patients with stable blood pressure and not in need for other treatments; No need for organ support, which comprises need for vasopressors or inotropes, mechanical ventilation, extra corporal circulation or renal replacement therapy
  • Controls; Patients as the pneumocystis pneumonia patients, but where the diagnosis is rejected
  • Healthy controls for the confirmed PA patients and confirmed pneumocystis pneumonia patients In addition, 19 healthy controls (i.e. patients/subjects who undergo diagnostic work-up for benign or indolent hematological diseases without suspected PA or pneumocystis pneumonia) will be recruited, as described below; Healthy controls and patients who are going through diagnostic work-up for indolent hematological cancer types or benign hematological diseases, at the Department of Hematology, Aalborg University Hospital; Same gender and age (within a 10-year range) as an included patient with proven/probable/possible PA (15 subjects); Same gender and age (within a 10-year range) as an included patient with verified pneumocystis pneumonia (4 subjects); Are conscious and able to understand the given study information; Possess legal capacity; Age above 18 years; Informed, signed consent is obtained

Ki nem vehet részt

  • PA patients, pneumocystis pneumonia patients and controls:; No upper age limit will be applied

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

In this study, a new, non-invasive method for diagnosis of pulmonary aspergillosis (PA) will be tested in a clinical pilot project.

A vizsgálat 6 csoportja

  • PA proven/probable/possible

    15 patients with proven, probable or possible PA

    Kezelés: Aspergillus specific proteins in exhaled breath condensate (EBC)

  • PA suspected, not confirmed

    15 patients as the PA patients, but where the diagnosis of PA is rejected.

    Kezelés: Aspergillus specific proteins in exhaled breath condensate (EBC)

  • Healthy controls (PA)

    15 subjects of same gender and age as an included patient with proven/probable/possible PA as healthy controls.

    Kezelés: Aspergillus specific proteins in exhaled breath condensate (EBC)

  • Pneumocystis pneumonia positive

    Four patients with confirmed pneumocystis pneumonia

    Kezelés: Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)

  • Pneumocystis pneumonia negative

    If the diagnosis of pneumocystis pneumonia is not confirmed in a patient with suspected pneumocystis pneumonia, the patient will be included as negative control. Four such patients will be included as healthy controls.

    Kezelés: Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)

  • Healthy controls (pneumocystis pneumonia)

    Four subjects of same gender and age as an included patient with verified pneumocystis pneumonia as healthy controls.

    Kezelés: Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2024. február 13.